江苏康宁杰瑞生物制药有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Alphamab Oncology Presented Final Analysis of KN046 Combined with Nab-paclitaxel in the Treatment of mTNBC at SABCS 2022 2022-12-12 10:33
Better treatments for breast cancer! Latest Clinical Data of Bispecific Antibodies will be presented at SABCS 2022 By Alphamab Oncology 2022-11-22 09:18
Data from KN046 in Patients with metastatic NSCLC who failed first line treatment or prior EGFR-TKIs Presented at ESMO 2022 2022-09-14 09:11
Alphamab Oncology Presents the updated data from Phase 2 Clinical trial on KN046 Combined with platinum doublet chemotherapy as first-line（1L）treatment for NSCLC at ESMO 2022 2022-09-14 09:04
Updated Data Presented for KN026 comboKN046 in 1st Line HER2-Positive Gastric/Gastroesophageal Junction Cancer (GC/GEJ) 2022-09-14 09:01
First Patient Dosed in Phase II Study of KN046 Combined with Axitinib for the First Line Treatment of Advanced Non-Small Cell Lung Cancer 2022-08-09 11:18
Alphamab Oncology Announced First Patient Dosed in Phase I Trial of PD-L1/OX40 Bispecific Antibody KN052 2022-06-14 08:58
Poster Highlighting Phase II Clinical Study of KN026 for HER2-expressing Advanced GC/GEJ Presented at 2022 ASCO 2022-06-06 10:49
Research Updates on KN046 Presented at 2022 ASCO 2022-06-06 09:47
First Year of Commercialization, Alphamab Oncology Reports Full Year 2021 Financial Results and Business Highlights 2022-03-30 10:36
First Year of Commercialization, Alphamab Oncology Reports Full Year 2021 Financial Results and Business Highlights 2022-03-30 10:35
Alphamab Oncology to Present Clinical Data of KN026 Combined with KN046 in HER2-positive Solid Tumors at AACR 2022 2022-03-09 09:14
Alphamab Oncology Announced Publication of Clinical Results of KN026 in HER2-positive Breast Cancer in Clinical Cancer Research 2022-02-24 09:41
Alphamab Oncology Announced IND Approval of PD-L1/OX40 Bispecific Antibody KN052 2022-02-11 09:31
Enrollment Completed in Phase II Clinical Study of KN026 Combined with KN046 2022-01-13 10:46
IND Approved for Pivotal Clinical Study of HER2 Bispecific Antibody KN026 Combined with Chemotherapy in Gastric Cancer 2022-01-05 11:49
Alphamab Oncology Announced First Patient Dosed in the U.S. in A Phase II Pivotal Clinical Study of KN046 2021-12-23 09:13
Posters Highlighting clinical data of KN026 presented at SABCS 2021 2021-12-09 12:20
IND Application for Phase 3 Registration Study of KN046 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer was Approved by CDE 2021-11-24 09:35
Alphamab Oncology Announces First Patient Dosed in the Pivotal Clinical Study of KN046 for the Treatment of PD-(L)1 Refractory Advanced NSCLC 2021-10-29 09:36
1 2 3 4